Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 10, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 31,738 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on November 9, 2005, and was advised to the Company on November 10, 2005.
Outlook, Risks, and Management Commentary
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held by the trust in the same capacity as other employees. No specific guidance, outlook, or risk factors regarding business operations are disclosed in this text.
Investor Verification Points
- Verify the impact of the 31,738 share transfer on the total outstanding share count.
- Confirm the specific allocation of shares among participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Review the full terms of the GSK Trust to understand the scope of director interests.